BillionToOne, Inc. (BLLN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | 72 | 153 | 305 | 397 | 456 |
| Operating profit | $m | 16 | 43 | ||||||
| Net profit | $m | - | - | - | -83 | -42 | 7 | 34 | 38 |
| EPS reported | $ | 0.16 | 0.62 | ||||||
| Operating cashflow per share | $ | 0.54 | 0.98 | ||||||
| Capex per share | $ | 0.19 | 0.26 | ||||||
| FCF per share | $ | 0.34 | 0.71 | ||||||
| Free cash flow | $m | 16 | 33 | ||||||
| Net debt | $m | -433 | -458 | ||||||
| Book value equity | $m | 480 | 537 | ||||||
| Book value per share | $ | 10.48 | 9.86 | ||||||
| Number of shares | m | 45.8 | 54.46 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | 198.48 | ||||||
| P/B LTM | x | 7.81 | 6.98 | ||||||
| P/S LTM | x | 12.29 | 9.43 | ||||||
| P/FCF LTM | x | 238.56 | 113.00 | ||||||
| EV/EBITDA LTM | x | 170.11 | 66.90 | ||||||
| EV/Sales LTM | x | 11.02 | 10.48 | ||||||
| Earnings Yield LTM | % | +0.20% | +0.50% | ||||||
| FCF Yield | % | +0.42% | +0.88% | ||||||
| Quality | |||||||||
| ROE | % | +1.55% | +7.87% | ||||||
| ROIC | % | +2.61% | +6.33% | ||||||
| Operating margin | % | +5.25% | +10.90% | ||||||
| Gross margin | % | +68.32% | +71.27% | ||||||
| FCF/Sales | % | +5.15% | +8.35% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +99.97% | +160.46% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.14 | 0.23 | ||||||
| Net Debt/EBITDA | x | -19.59 | -8.05 | ||||||
| EBIT/Net interest | x | 168.66 | 1,056.15 | ||||||
| Net debt/market cap | % | +1.68% | +1.99% | ||||||
| Net debt/Equity | x | -0.90 | -0.85 | ||||||
| Gross debt/equity | x | 0.23 | 0.27 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free